BOV Stock Chart & Stats
€2.60
-€0.04(-1.20%)
At close: 4:00 PM EDT
€2.60
-€0.04(-1.20%)
Day’s Range― - ―
52-Week Range€1.66 - €4.14
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€109.47M
Enterprise Value€209.33
Total Cash (Recent Filing)€27.62M
Total Debt (Recent Filing)€39.63M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 05, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding42,124,023
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)10.15
Price to Sales (P/S)2.79
P/FCF Ratio-16.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.72Price Target Upside119.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.23
Revenue Forecast (FY)€52.17M
Bulls Say, Bears Say
Bulls Say
Revenue And Surgical Aesthetics GrowthStrong Surgical Aesthetics growth and reaffirmed full-year guidance indicate expanding demand for Apyx’s core platform. Continued growth in domestic, international, and recurring handpiece sales can increase the installed base and support procedure-linked revenue over the next several quarters.
FDA-Cleared Product ExpansionExpanded FDA clearance broadens AYON’s clinical functionality and strengthens Apyx’s addressable procedure opportunity. Management expects more than 95% of new AYON purchasers to include Power Lipo, which could improve adoption, utilization, and recurring accessory demand as the launch scales.
Improving Gross ProfitabilityHigher gross profit and a 160-basis-point margin improvement show operating progress alongside revenue growth, while narrower operating and adjusted EBITDA losses indicate better cost absorption. If sustained, this trend can move the company closer to profitability and improve internal funding capacity.
Bears Say
Persistent Losses And Cash BurnApyx remains dependent on external funding capacity because operations are not yet generating cash internally. Continued losses and negative free cash flow can constrain investment in commercialization, increase financing needs, and reduce flexibility if the expected improvement in working capital and margins is delayed.
Elevated Leverage And Thin Equity CushionDebt materially exceeds the company’s equity base, making the balance sheet sensitive to execution setbacks and prolonged losses. Elevated leverage can limit strategic flexibility, increase dependence on financing, and leave fewer resources available to fund product expansion while cash generation remains negative.
Declining OEM RevenueThe OEM business is shrinking and management expects the decline to continue during 2026 and beyond. This creates a durable drag on the revenue mix, requiring Surgical Aesthetics and newer products to grow fast enough to offset lost OEM contribution and sustain overall operating leverage.
Apyx Medical News
BOV FAQ
What was Apyx Medical Corporation’s price range in the past 12 months?
Apyx Medical Corporation lowest stock price was €1.66 and its highest was €4.14 in the past 12 months.
What is Apyx Medical Corporation’s market cap?
Apyx Medical Corporation’s market cap is €109.47M.
When is Apyx Medical Corporation’s upcoming earnings report date?
Apyx Medical Corporation’s upcoming earnings report date is Nov 05, 2026 which is in 37 days.
How were Apyx Medical Corporation’s earnings last quarter?
Apyx Medical Corporation released its earnings results on Aug 06, 2026. The company reported -€0.061 earnings per share for the quarter, beating the consensus estimate of -€0.071 by €0.01.
Is Apyx Medical Corporation overvalued?
According to Wall Street analysts Apyx Medical Corporation’s price is currently Undervalued.
Does Apyx Medical Corporation pay dividends?
Apyx Medical Corporation does not currently pay dividends.
What is Apyx Medical Corporation’s EPS estimate?
Apyx Medical Corporation’s EPS estimate is -0.08.
How many shares outstanding does Apyx Medical Corporation have?
Apyx Medical Corporation has 42,124,023 shares outstanding.
What happened to Apyx Medical Corporation’s price movement after its last earnings report?
Apyx Medical Corporation reported an EPS of -€0.061 in its last earnings report, beating expectations of -€0.071. Following the earnings report the stock price went down -1.136%.
Which hedge fund is a major shareholder of Apyx Medical Corporation?
Currently, no hedge funds are holding shares in DE:BOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apyx Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.72 (119.93% Upside)
€5.72 (119.93% Upside)
Blogger Sentiment
Bearish
DE:BOV Sentiment 100%
Sector Average 64%
Sector Average 64%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
BOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented solid commercial and clinical momentum: double-digit top-line growth (22% total, 28% surgical aesthetics), improved gross profit/margin and narrower operating and adjusted EBITDA losses, supported by FDA clearance for power liposuction and favorable clinical data. Offsetting risks include continued OEM decline, increased operating cash use and near-term manufacturing/cost pressures for new Power Lipo units, plus tariff-related cost uncertainty. On balance, the positive revenue and margin trends, clinical validation, product approvals and reaffirmed guidance outweigh the challenges.View all DE:BOV earnings summariesBOV Stock 12 Month Forecast
Average Price Target
€5.72
▲(119.93% Upside)